Cramer Gives His Opinion On Fitbit And Allergan

by Craig Jones, Benzinga Staff Writer

April 3, 2016 4:48 PM | 1 min read | Make a Comment

Jim Cramer said on

that he was wrong on

Fitbit IncFIT

, but he still likes it and wants to buy it. The stock is down 50 percent year to date, but people still think that it is expensive. He believes that the selling is overdone.

Cramer explained that Allergan plc Ordinary Shares AGN is not trading higher because some people are speculating that the merger with Pfizer Inc. PFE won't get through. He added that there is also a lot of scrutiny because of the tax aversion issue and that the stock is stagnating because the biotech space is currently out of favor.

Market News and Data brought to you by Benzinga APIs

Posted In: Analyst Color Biotech CNBC Long Ideas Health Care Media Trading Ideas General Jim Cramer Mad Money

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!